ValiRx plc (GB:VAL) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
ValiRx PLC’s subsidiary, Inaphaea BioLabs, has secured a significant contract with Amply Discovery Limited to provide cell-based assays for evaluating siRNA targets in breast cancer treatment. The deal, potentially worth over £100,000, marks a strategic partnership and showcases Inaphaea’s comprehensive service capabilities. This collaboration underscores ValiRx’s commitment to advancing cancer therapeutics and women’s health solutions.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.